Advertisement

Topics

Transgene S.A. Company Profile

10:24 EDT 23rd June 2018 | BioPortfolio

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.


News Articles [27 Associated News Articles listed on BioPortfolio]

Transgene (TNG) - 2018: A year of clinical data

Edison Investment Research - Pharmaceutical & healthcare - Transgene: We anticipate nine of Transgene’s ongoing clinical trials to read out data later this year. This will be the first major tes...

Transgene doses first patient in Phase l study of T101

French biotechnology company Transgene has dosed the first patient in a Phase l clinical trial in China to assess T101...Read More... The post Transgene doses first patient in Phase l study of T101 ap...

Transgene and Randox to develop innovative multifunctional oncolytic virotherapies for solid tumors

Novel oncolytic virotherapies will be developed by Transgene, based on its next generation Invir.IO Platform and expressing Randox single-domain antibodies (SdAb)

Transgene: Combined General Meeting of May 23, 2018

Regulatory News: Transgene’s (Paris:TNG) shareholders held their Combined General Meeting (ordinary and extraordinary) today, chaired by Philippe Archinard, Chai...

First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s ...

Read more...

Transgene: Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018

Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies announced that the Combined G...

First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for ...

First results expected in H2 2018 Read more...

Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018

Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, will be presenting a poster with new and...

Drugs and Medications [0 Results]

None

PubMed Articles [49 Associated PubMed Articles listed on BioPortfolio]

Synthetic switch-based baculovirus for transgene expression control and selective killing of hepatocellular carcinoma cells.

Baculovirus (BV) holds promise as a vector for anticancer gene delivery to combat the most common liver cancer-hepatocellular carcinoma (HCC). However, in vivo BV administration inevitably results in ...

Application of droplet digital PCR in the analysis of genome integration and organization of the transgene in BAC transgenic mice.

Transgenic (Tg) mice containing bacterial artificial chromosome (BAC) DNA are widely used for gene expression analysis and gene therapy models because BAC transgenes provide gene expression at physiol...

Effects of Different Promoters and Combinations on Transgene Expression of Recombinant CHO Cells.

To analyze the effects of different promoters and matrix attachment region (MAR) on the expression of transgene in Chinese hamster ovary (CHO) cells.

Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation.

A critical issue in transgene delivery studies is immune reactivity to the transgene- encoded protein and its impact on sustained gene expression. Here, we test the hypothesis that immunomodulation by...

Human rhinovirus internal ribosome entry site element enhances transgene expression in transfected CHO-S cells.

Chinese hamster ovary (CHO) cells are mainly used for recombinant protein production. However, the unstable transgene expression and lower transgene copy numbers are the major issues need to be resolv...

Clinical Trials [8 Associated Clinical Trials listed on BioPortfolio]

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

The primary objective is to evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue, at injection site, after Intra Muscular (IM) administration of increasing single...

Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Evaluation of Safety, Tolerability, and Efficacy of XT-150, a plasmid DNA with a variant of human IL-10 transgene. XT-150 will be a single injection into the knee synovial capsule for the ...

Performance of the HBV ELISPOT in the Detection of the T Cellular Immune Response in Patients Infected by HBV or Cured

Activation of the immune system against a pathogen can be considered one of the most effective interventions in the field of infectious diseases. Transgene is developing a therapeutic vac...

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis dur...

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic metabolic disorder characterized by absent or severely reduced capacity to catabolize circulating LDL particles by the hep...

Companies [9 Associated Companies listed on BioPortfolio]

Transgene S.A.

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for th...

Transgene SA

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for th...

Transgene

TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited d...

Intrexon Corporation

Intrexon Corporation is a privately held life sciences company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutic...

Transgene Inc

Mission StatementTransgene is a biopharmaceutical company dedicated to the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infec...

More Information about "Transgene S.A." on BioPortfolio

We have published hundreds of Transgene S.A. news stories on BioPortfolio along with dozens of Transgene S.A. Clinical Trials and PubMed Articles about Transgene S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Transgene S.A. Companies in our database. You can also find out about relevant Transgene S.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record